Future work might extend these analyses to include other biomarkers, such as disease-specific molecules (e.g. phosphorylated tau in AD), other neurological diseases (e.g. inflammatory diseases such as multiple sclerosis) and systematically study the effects of different handling/storage protocols to further optimize accuracy. This evidence concerns the gene MAPT and multiple sclerosis.